Is it Time for a Paradigm Change in HIV Management?

The Evolution of HIV Management

TEMPRANO Study

TEMPRANO Study: Serious Events

Test and Treat Strategy

When to Treat: Unanswered Questions

Communicating With the Patient

The Shift to Integrase Inhibitors

Increased Risk of Suicidality in Patients Treated With EFV-Containing Regimens

Increased Risk of Suicidal Behavior With Use of EFV: Results From the START Trial

Use of Integrase Inhibitors Worldwide

Integrase Inhibitor Efficacy Data

Minimal Drug Interactions With Integrase Inhibitors

Tuberculosis and Drug Interactions

Is it Beneficial To Use Fewer Agents?

PADDLE: Viral Suppression at Week 48 With a 2-Drug Regimen (Dolutegravir/3TC)

Dual Therapy

ONCEMRK: RAL 1200 mg Once Daily Noninferior to RAL 400 mg Twice Daily at Wk 48

Choosing the Optimal Dual Therapy Treatment

The Use of Injectables in Dual Therapy

LATTE-2: Cabotegravir IM + Rilpivirine IM for Long-Acting Maintenance ART

LATTE-2: Efficacy and Safety Through Maintenance Wk 48

LATTE-2: Determining Optimal Dose Interval for Future Studies

LATTE-2: Acceptability of Injections

The Use of Cabotegravir for PrEP

HPTN083 Trial

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)